1 Up-and-Coming Cannabis Stock to Consider

Neptune Wellness Solutions Inc (TSX:NEPT) (NASDAQ:NEPT) might be an excellent cannabis stock to consider; here is why.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Most cannabis stocks started the year on a high note, but most have encountered some difficult times over the last few months. Various things have contributed to this lackluster collective performance.

First, global equity markets slowed down during the second quarter of the year. Second, several scandals have negatively affected the cannabis industry specifically. One of these was the drama surrounding CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST). 

In case you aren’t aware, CannTrust was caught growing marijuana in illegal rooms. This revelation led to the firm’s stock shedding much of its value, and it likely played a role in dragging down the entire marijuana sector.

Despite these headwinds, some pot stocks are performing relatively well, and one of these is Neptune Wellness Solutions Inc (TSX:NEPT) (NASDAQ:NEPT). 

Core operations 

Unlike many of its peers in the marijuana sector, Neptune has been around for more than two decades. However, the firm just recently entered the pot industry. Neptune submitted an application to become a licensed processor of cannabis and hemp oil back in 2017.

The company specializes in the extraction of cannabinoids from cannabis and hemp plants to use in healthcare products. This sector presents an important advantage over the dried cannabis segment: it offers companies higher margins.

Of course, other firms are looking to profit from this high-margin opportunity, so the competition is fierce. But Neptune does have several things going its way. 

Back in June, the Quebec-based firm signed an agreement with one of the giants of the marijuana sector, namely Tilray Inc (NASDAQ:TLRY).

Under the terms of the agreement, Neptune will provide extraction and purification services to Tilray, processing a minimum of 125,000 kilograms of cannabis and hemp biomass over three years.

Just about a week after announcing its agreement with Tilray, Neptune announced a similar one with The Green Organic Dutchman Ltd (TSX:TGOD).

Under this deal, Neptune will provide extraction, formulation and packaging services to TGOD, processing over 230,000 kilograms of cannabis and hemp biomass also over a period of three years. These agreements should help boost the firm’s top line in the future. 

Why the future may be bright for Neptune

One reason why investors might look positively towards Neptune is the fact that the CBD market is heating up. This segment of the broader sector is projected to outpace most others.

CBD not only provides health benefits, but as it lacks the psychoactive ingredient known as tetrahydrocannabinol (or rather, possesses negligible traces of it), it is likely to attract a large segment of the population.

Further, medical patients are generally more likely to spend money on cannabis products than recreational users. Neptune is looking to become one of the leaders in the CBD extraction sector, and as the market grows, the firm might secure more supply agreements, or at least, will generally have more business coming its way. 

The bottom line

Neptune’s financial results haven’t been particularly impressive, but the company occupies a promising segment of the marijuana industry. Neptune has also been one of the best performing marijuana firms on the stock market year to date.

While the firm doesn’t yet scream “buy,” at least in my opinion, it would be wise to keep an eye on Neptune Wellness.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »